 |
|
 |
 |

Home > Company Index > Drugs > Drug Manufacturers - Other > Xenova Group plc
 |
Xenova Group plc |
 |
 |
 |
PROFILE |
 |
Xenova Group has traded homemade cures for high-tech medicine. The drug development company sold the assets of Xenova Discover and MetaXen, subsidiaries that developed pharmaceuticals from plants and other natural compounds, and is now focused on developing small molecule cancer treatments that can be administered orally or intravenously. One of its two lead drugs in development, XR5000, has not fared well in testing; the drug candidate aims to inhibit tumor growth. Its other drug candidate is XR9576, which targets a protein related to the multi-drug resistance of some cancers. Xenova Group has bought Cantab Pharmaceuticals to expand its pipeline, especially in the area of cancer drugs.
COMPETITION |
 |
Axys Pharmaceuticals, Inc. (AXPH)
Cell Therapeutics, Inc. (CTIC)
NeoPharm, Inc. (NEOL)
|
 |
STOCK ANALYSIS |
 |
FURTHER ANALYSIS
Advanced Charting
Deals
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: December
2000 Sales (mil.): 0.10
1-Yr. Sales Growth: (83.3)%
Employees: 57
Revenue per employee: $1,754.39
KEY PEOPLE |
 |
David A. Oxlade
CEO
Daniel Abrams
CFO
CONTACT INFO |
 |
240 Bath Rd.
Slough Berkshire SL1 4EF, United Kingdom
Phone: 44-1753-706-600
Fax: 44-1753-706-607
Online: Web Site
|
 |
 |
 |
|
Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.
|

|
 |
 |
|
 |